CF
ANIP icon

Corebridge Financial’s ANI Pharmaceuticals ANIP Stock Holding History

Corebridge Financial’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,595
Closed -$642K – 176
2025
Q1 		$642K Sell
9,595
-183
-2% -$10.9K ﹤0.01% 1459
2024
Q4 		$541K Sell
9,778
-762
-7% -$43.7K ﹤0.01% 1647
2024
Q3 		$629K Sell
10,540
-54
-0.5% -$3.29K ﹤0.01% 1608
2024
Q2 		$675K Buy
+10,594
New +$688K ﹤0.01% 1542

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Corebridge Financial's ANIP Position: Q2 2025 in Review

Corebridge Financial sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 9,595 shares — an estimated $642K sold.

Corebridge Financial first reported a position in ANIP in Q2 2024 and held it in 4 quarters. The position peaked at $675K in Q2 2024. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Corebridge Financial reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 9,595 ANI Pharmaceuticals shares in Q2 2025, an estimated $642K.
  • Corebridge Financial first reported a position in ANI Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ANI Pharmaceuticals position peaked at $675K in Q2 2024.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.